Arbutus Biopharma (ABUS) Share-based Compensation (2012 - 2026)
Arbutus Biopharma (ABUS) posted Share-based Compensation of $1.4 million for Q1 2026, up 7.69% sequentially from $1.3 million in Q4 2025, and down 61.87% YoY from $3.6 million in Q1 2025.
Arbutus Biopharma (ABUS) Share-based Compensation (2012 - 2026) Analysis & Trends
Arbutus Biopharma has reported Share-based Compensation for 15 years, with the latest figure at $1.4 million in Q1 2026.
- Quarterly Share-based Compensation fell 61.87% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (down 54.94% YoY) and the FY2025 annual result came in at $7.0 million, down 22.62% from the prior year.
- Share-based Compensation advanced to $1.4 million in Q1 2026 per ABUS's latest filing, from $1.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $3.6 million in Q1 2025 and troughed at $864000.0 in Q2 2025.
- A 5-year average of $2.0 million and a median of $1.7 million in 2022 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 76.96% in 2025, down 72.83% in 2025.
- Over 5 years, Share-based Compensation stood at $1.7 million in 2022, then gained by 3.36% to $1.7 million in 2023, then decreased by 5.28% to $1.6 million in 2024, then dropped by 22.67% to $1.3 million in 2025, then grew by 7.69% to $1.4 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.4 million, $1.3 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | 1.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.63 Mn |
| Jun 30, 2026 | 1.63 Mn |
| Mar 31, 2026 | 1.36 Mn |
| Mar 31, 2026 | 1.36 Mn |
| Dec 31, 2025 | 1.26 Mn |
| Dec 31, 2025 | 1.26 Mn |
| Sep 30, 2025 | 1.26 Mn |
| Sep 30, 2025 | 1.26 Mn |
| Jun 30, 2025 | 864,000.00 |
| Jun 30, 2025 | 864,000.00 |
| Mar 31, 2025 | 3.56 Mn |
| Mar 31, 2025 | 3.56 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Jun 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 3.18 Mn |
| Mar 31, 2024 | 2.01 Mn |
| Mar 31, 2024 | 2.01 Mn |